Citadel Advisors
PTPI

Citadel Advisors’s Petros Pharmaceuticals PTPI Stock Holding History

Citadel Advisors’s Portfolio PTPI Stock Details PTPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-654
Closed -$83K – 15336
2022
Q3 		$83K Buy
654
+591
+938% +$107K ﹤0.01% 11247
2022
Q2 		$13K Sell
63
-164
-72% -$41.1K ﹤0.01% 12525
2022
Q1 		$89K Buy
227
+166
+272% +$70K ﹤0.01% 12392
2021
Q4 		$51K Buy
+61
New +$35.7K ﹤0.01% 13243

Other funds holding PTPI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's PTPI Position: Q4 2023 in Review

Citadel Advisors sold out of Petros Pharmaceuticals (PTPI) in Q4 2023, closing a stake of 572 shares — an estimated $23.7K sold.

Citadel Advisors first reported a position in PTPI in Q1 2021 and held it in 7 quarters. The position peaked at $131K in Q1 2021. 12 funds tracked by Wall St. Rank hold PTPI as of Q4 2023.

  • Citadel Advisors reported no remaining Petros Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 572 Petros Pharmaceuticals shares in Q4 2023, an estimated $23.7K.
  • Citadel Advisors first reported a position in Petros Pharmaceuticals in Q1 2021 and held it in 7 quarters.
  • Citadel Advisors's Petros Pharmaceuticals position peaked at $131K in Q1 2021.
  • 12 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.